Develops RIPTAC™ therapeutics, a novel class of precision cancer treatments that use a protein-protein interaction mechanism to selectively bind tumor-specific proteins and essential cellular functions, leading to targeted cancer cell death. This approach addresses the limitations of traditional therapies by offering a more precise and effective method for treating major solid tumors.
Funding
$227.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer therapies often lack the precision needed to target tumor cells effectively, leading to off-target effects and drug resistance. Many current treatments rely on targeting oncogenic drivers, which cancer cells can bypass, resulting in relapse and limited efficacy against major solid tumors.
Solution
Halda Therapeutics is developing RIPTAC™ (Regulated Induced Proximity TAC) therapeutics, a novel class of precision medicines designed to selectively target and eliminate cancer cells. RIPTACs employ a "hold-and-kill" mechanism, inducing a protein-protein interaction between a tumor-specific protein and another protein essential for cell survival. This induced proximity leads to the selective killing of cancer cells while overcoming common drug resistance mechanisms. The RIPTAC platform aims to address the unmet needs of patients with drug-resistant cancers by offering a more targeted and effective approach to treating major solid tumors.
Target Audience
The primary target audience includes patients with major solid tumors, particularly those with drug-resistant cancers, and the clinicians who treat them.
Features
- RIPTAC™ (Regulated Induced Proximity TAC) technology platform for creating precision cancer therapeutics
- "Hold-and-kill" mechanism inducing proximity between tumor-specific and essential proteins
- Designed to overcome bypass mechanisms of drug resistance
- Selective targeting of cancer cells, minimizing off-target effects
- Pipeline of RIPTAC therapeutics for major cancer types
- HLD-0915, an oral RIPTAC therapeutic in Phase 1 clinical trials for metastatic castrate resistant prostate cancer (mCRPC)